Olanzapine Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0089 
Minor change in labelling or package leaflet not 
22/09/2023 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IA/0088/G 
This was an application for a group of variations. 
14/08/2023 
n/a 
A.7 - Administrative change - Deletion of 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0087 
Minor change in labelling or package leaflet not 
11/10/2021 
24/03/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0086 
B.II.d.2.d - Change in test procedure for the finished 
08/06/2021 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IA/0085/G 
This was an application for a group of variations. 
03/03/2021 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0084 
A.7 - Administrative change - Deletion of 
01/03/2021 
24/03/2022 
Annex II and 
manufacturing sites 
PL 
IA/0083 
B.III.1.a.2 - Submission of a new/updated or 
14/01/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 2/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0082 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/04/2020 
31/07/2020 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IA/0081 
B.III.1.a.2 - Submission of a new/updated or 
12/12/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0080/G 
This was an application for a group of variations. 
23/10/2019 
31/07/2020 
SmPC and PL 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IB/0079 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/07/2019 
31/07/2020 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
N/0077 
Minor change in labelling or package leaflet not 
29/04/2019 
31/07/2020 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
Page 3/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0078/G 
This was an application for a group of variations. 
25/04/2019 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0076 
B.III.1.a.2 - Submission of a new/updated or 
19/04/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0075 
Minor change in labelling or package leaflet not 
19/02/2018 
31/07/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0074 
Minor change in labelling or package leaflet not 
28/11/2017 
19/02/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0073 
B.II.b.4.b - Change in the batch size (including batch 
11/05/2017 
n/a 
size ranges) of the finished product - Downscaling 
down to 10-fold 
IB/0072 
B.II.b.3.z - Change in the manufacturing process of 
15/03/2017 
n/a 
the finished or intermediate product - Other variation 
IAIN/0071 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/02/2017 
19/02/2018 
SmPC and PL 
Page 4/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veterinary Medicinal Products - Other variation 
IA/0070 
B.II.b.3.a - Change in the manufacturing process of 
08/12/2016 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IAIN/0069/G 
This was an application for a group of variations. 
02/12/2016 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IA/0068 
B.III.2.a.2 - Change of specification(s) of a former 
07/10/2016 
n/a 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
IAIN/0067 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/07/2016 
21/10/2016 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IA/0066 
B.III.1.a.2 - Submission of a new/updated or 
15/06/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 5/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0064/G 
This was an application for a group of variations. 
26/05/2016 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IA/0065/G 
This was an application for a group of variations. 
18/03/2016 
21/10/2016 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IAIN/0062/G 
This was an application for a group of variations. 
11/11/2015 
21/10/2016 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
Page 6/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
Page 7/27 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
Page 8/27 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IAIN/0063/G 
This was an application for a group of variations. 
09/11/2015 
21/10/2016 
SmPC, 
Labelling and 
PL 
B.II.c.3.z - Change in source of an excipient or 
reagent with TSE risk - Other variation 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0061 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
05/10/2015 
21/10/2016 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0060 
B.II.e.7.a - Change in supplier of packaging 
01/07/2015 
n/a 
components or devices (when mentioned in the 
Page 9/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
dossier) - Deletion of a supplier 
T/0059 
Transfer of Marketing Authorisation 
12/03/2015 
09/04/2015 
SmPC, 
Labelling and 
PL 
IB/0058 
B.II.e.1.z - Change in immediate packaging of the 
27/01/2015 
09/04/2015 
SmPC, 
finished product - Other variation 
Labelling and 
PL 
II/0055/G 
This was an application for a group of variations. 
22/01/2015 
09/04/2015 
SmPC, Annex 
II, Labelling 
and PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.a.2.a - Change in the shape or dimensions of the 
pharmaceutical form - Immediate release tablets, 
capsules, suppositories and pessaries 
B.II.a.3.a.1 - Changes in the composition 
(excipients) of the finished product - Changes in 
components of the flavouring or colouring system - 
Addition , deletion or replacement 
B.II.a.3.b.2 - Changes in the composition 
(excipients) of the finished product - Other excipients 
- Qualitative or quantitative changes in one or more 
excipients that may have a significant impact on the 
safety, quality or efficacy of the product 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
Page 10/27 
 
 
 
 
 
 
 
 
 
 
 
 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.3.b - Change in the manufacturing process of 
the finished or intermediate product - Substantial 
changes to a manufacturing process that may have a 
significant impact on the quality, safety and efficacy 
of the medicinal product 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
Page 11/27 
 
 
 
 
 
its corresponding test method 
B.II.d.1.d - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.II.f.1.a.1 - Stability of FP - Reduction of the shelf 
life of the finished product - As packaged for sale 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Page 12/27 
 
 
 
 
 
Not including batch control/testing 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0056/G 
This was an application for a group of variations. 
03/10/2014 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
Page 13/27 
 
 
 
 
 
 
 
 
 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0054/G 
This was an application for a group of variations. 
16/09/2014 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
IB/0057 
Update of sections 4.4 and 5.1 of the SmPC in order 
27/08/2014 
09/04/2015 
SmPC and PL 
to reflect the level of data available in adolescents 
Page 14/27 
 
 
 
 
 
 
 
 
 
 
 
with bipolar I disorder (manic or mixed episodes) or 
schizophrenia following the completion of a long-
term safety study, to fulfil the requirement laid down 
in Article 46 of the paediatric regulation following the 
same change for the originator. 
The MAH took also the opportunity to align the 
Product Information with the QRD template (Version 
9). 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0053 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
23/09/2013 
28/02/2014 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0052 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/08/2013 
28/02/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II and PL 
IAIN/0051 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/05/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0050/G 
This was an application for a group of variations. 
01/03/2013 
28/02/2014 
SmPC, 
Page 15/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Labelling and 
PL 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
Page 16/27 
 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
R/0048 
Renewal of the marketing authorisation. 
20/09/2012 
12/11/2012 
Based on the CHMP review of the available information and 
on the basis of a re-evaluation of the benefit risk balance, 
the CHMP was of the opinion that the quality, safety and 
efficacy of this medicinal product continues to be 
adequately and sufficiently demonstrated and therefore 
considered that the benefit risk profile of Olanzapine Teva 
continues to be favourable. 
IB/0049 
Update of the section 4.8 of the SmPC to add urinary 
20/09/2012 
12/11/2012 
SmPC, Annex 
II, Labelling 
and PL 
retention as an undesirable effect and to reflect this 
change in the section 4 of the PLs further to a 
cumulative review of “urinary retention” in temporal 
association with olanzapine treatment in line with the 
reference medicinal product. In addition, changes are 
proposed throughout the product information to 
bring it in line with version 8 of the QRD template. In 
addition, contact details for local representatives 
have been updated. Also, changes in the text for 
Czech Republic, Germany, Hungary, Norway, 
Portugal, Italy and Spain were implemented in line 
with the reference medicinal product. 
Page 17/27 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IAIN/0047/G 
This was an application for a group of variations. 
05/07/2012 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0046/G 
This was an application for a group of variations. 
25/06/2012 
n/a 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.c - Change in the specification parameters 
Page 18/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.c.3.b - Change in test procedure for the 
immediate packaging of the AS - Other changes to a 
test procedure (including replacement or addition) 
IB/0045 
B.II.d.1.z - Change in the specification parameters 
19/04/2012 
n/a 
and/or limits of the finished product - Other variation 
IB/0044 
Following PhVWP/CHMP conclusions of June 2011, 
13/01/2012 
08/08/2012 
SmPC and PL 
update of the Summary of Product Characteristics 
(SmPC) and Package Leaflet (PL) in line with the 
reference medicinal product regarding the use of 
antipsychotics during the third trimester of 
pregnancy and risk of abnormal muscle movements 
and/or withdrawal symptoms in newborns in 
accordance with the PhVWP/CHMP class labelling 
recommended wording. In addition, contact details 
for local representatives in Malta and Italy have been 
updated. A correction related to the product name 
has been made in the Dutch annex. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IAIN/0043 
A.5.a - Administrative change - Change in the name 
15/12/2011 
17/02/2012 
SmPC, Annex 
Page 19/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or address of a manufacturer responsible for 
II and PL 
batch release 
IAIN/0042/G 
This was an application for a group of variations. 
10/11/2011 
17/02/2012 
Annex II and 
PL 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IA/0041/G 
This was an application for a group of variations. 
19/08/2011 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
IB/0040 
Update of the section 4.4 of the Summary of Product 
12/11/2010 
n/a 
SmPC and PL 
Characteristics (deletion of a sentence in the warning 
related to hepatic function) and section 4.8 
(modification of the prolactin information in the 
footnote). Additionally, for all EEA languages, 
linguistic changes were made inline with the 
reference product information annexes. Furthermore, 
for EEA languages (EL, IT, PL and SL), minor spelling 
and grammatical corrections were made. 
Additionally, for EEA language HU, labelling text was 
updated to add active substance to Section 1. The 
Page 20/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product information annexes were also updated 
according to the QRD templates (version 7.3.1). 
Local Technical Representative name and contact 
details in the PIL texts were updated. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IA/0039 
B.II.d.1.a - Change in the specification parameters 
06/08/2010 
n/a 
SmPC and PL 
and/or limits of the finished product - Tightening of 
specification limits 
IB/0038 
Update of the sections 4.8 and 4.4 of the Summary 
31/03/2010 
n/a 
SmPC and PL 
of Product Characteristics (SPC) in line with the 
Product Information of the reference product 
regarding sudden cardiac death, urinary incontinence 
and information on elevated plasma prolactin 
concentrations and related clinical manifestations. 
Section 4 of the package leaflet has also been 
amended accordingly. Additionally, editorial changes 
were made in the relevant sections of the Product 
Information in line with the reference medicinal 
product. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 21/27 
 
 
 
 
 
 
 
 
 
 
 
new additional data are submitted by the MAH 
II/0037 
Update to section 4.8 of the Summary of Product 
24/09/2009 
19/10/2009 
SmPC 
The SPC was updated to align it with that of the reference 
Characteristics (SPC) in line with the Product 
Information of the reference medicinal products. An 
editorial change was made in section 4.4 of the SPC. 
Update of Summary of Product Characteristics 
medicinal products. This followed a change to the SPC of 
the reference medicinal products via the following 
procedures: Zyprexa (EMEA/H/C/000115/II/0099) and 
Zyprexa Velotab (EMEA/H/C/000287/II/0070). 
II/0036 
Update to sections 4.4 and 4.9 of the Summary of 
25/06/2009 
20/07/2009 
SmPC 
Following changes to the SPC of the reference medicinal 
Product Characteristics (SPC) in line with the Product 
product Zyprexa, section 4.4, 4.9 and 5.1 of the Olanzapine 
Information of the reference medicinal product 
Zyprexa. Section 5.1 of the SPC was also updated 
with regard to details of the ATC code. 
Update of Summary of Product Characteristics 
Teva SPC were updated. Recommendations on monitoring 
of patients for signs and symptoms of hyperglycaemia, 
worsening of glucose control and weight gain were added 
to section 4.4 and new information on acute overdose was 
added to section 4.9. Section 5.1 of the SPC was also 
updated with regard to details of the ATC code. The 
summary of the above mentioned changes may be found in 
the EPARs (module 8B) of Zyprexa (II/96) and Zyprexa 
Velotab (II/68). 
II/0034 
Update of Section 4.8 of the SPC in line with the 
23/10/2008 
21/11/2008 
SmPC 
Following a change to the SPC of the reference medicinal 
reference medicinal product. Some minor editorial 
changes have been introduced to keep the SPC in 
line with that for the reference product. 
product, Section 4.8 of the SPC of Olanzapine Teva were 
updated to align them with those of the reference medicinal 
product to include new data regarding changes in 
bodyweight, glucose and lipid levels over time in adults and 
Update of Summary of Product Characteristics 
adolescents. 
IB/0035 
IB_07_c_Replacement/add. of manufacturing site: 
23/09/2008 
n/a 
PL 
The summary of the above mentioned changes may be 
found in the EPARs (module 8B) of Zyprexa (II/92) and 
Zyprexa Velotab (II/61). 
Page 22/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
All other manufacturing operations ex. batch release 
IA_08_b_02_Change in BR/QC testing - repl./add. 
manuf. responsible for BR - incl. BC/testing 
II/0032 
Update of Sections 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of 
24/07/2008 
02/09/2008 
SmPC and PL 
Following a change to the SPC of the reference medicinal 
the SPC in line with the reference medicinal product. 
The Product Information was updated in accordance 
with the latest QRD templates. 
Update of Summary of Product Characteristics and 
Package Leaflet 
product, Sections 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SPC 
of Olanzapine Teva were updated to align them with those 
of the reference medicinal product to include data from 
studies conducted in adolescent population with 
schizophrenia and bipolar I disorder (manic or mixed 
episodes).  
The summary of the above mentioned changes may be 
found in the EPARs (module 8B) of Zyprexa (II/83) and 
Zyprexa Velotab (II/52). 
IB/0033 
IB_30_b_Change in supplier of packaging 
07/08/2008 
n/a 
components - replacement/addition 
IA/0031 
IA_08_b_01_Change in BR/QC testing - repl./add. 
11/06/2008 
n/a 
Annex II and 
manuf. responsible for BR - not incl. BC/testing 
PL 
IA/0030 
IA_08_b_01_Change in BR/QC testing - repl./add. 
11/06/2008 
n/a 
Annex II and 
manuf. responsible for BR - not incl. BC/testing 
PL 
II/0024 
Update of section 4.4 and 4.8 of Summary of Product 
24/04/2008 
10/06/2008 
SmPC and PL 
Following a change to the product information of its 
Characteristics and relevant section of the Package 
reference medicinal product, the SPC and PL of Olanzapine 
Leaflet. 
Neopharma was updated to align it with it.  
Update of Summary of Product Characteristics and 
Both existing warnings on diabetes and lipids alterations in 
Package Leaflet 
section 4.4 of the SPC have been updated. In addition, 
section 4.8 of the SPC was amended to add the term 
"glycosuria" as commonly occurring event, to amend the 
Page 23/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0028 
IB_07_c_Replacement/add. of manufacturing site: 
10/06/2008 
n/a 
Annex II and 
All other manufacturing operations ex. batch release 
IA_08_b_02_Change in BR/QC testing - repl./add. 
manuf. responsible for BR - incl. BC/testing 
PL 
IB/0027 
IB_14_a_Change in manuf. of active substance 
10/06/2008 
n/a 
without Ph. Eur. certificate - change in manuf. site 
IA/0029 
IA_32_b_Change in batch size of the finished 
29/05/2008 
n/a 
product - downscaling down to 10-fold 
N/0001 
Update of the list of local representatives in section 6 
07/03/2008 
n/a 
PL 
of the Package Leaflet. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0023 
IB_42_a_01_Change in shelf-life of finished product 
27/02/2008 
n/a 
SmPC 
- as packaged for sale 
IB/0021 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IB/0020 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
frequency of hyperglycaemia from very rare to rare, and to 
add further information in relation to weight gain, elevated 
glucose levels, elevated triglyceride levels and elevated 
cholesterol levels. The Package Leaflet was amended 
accordingly. 
Page 24/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
IB/0019 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IB/0018 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IB/0017 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IB/0016 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IB/0015 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IB/0014 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IB/0013 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IB/0012 
IB_41_a_02_Change in pack size - change in no. of 
08/02/2008 
08/02/2008 
SmPC, 
units outside range of appr. pack size 
Labelling and 
PL 
IA/0011 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
Page 25/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
IA/0010 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0009 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0008 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0007 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0006 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0005 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0004 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0003 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0002 
IA_41_a_01_Change in pack size - change in no. of 
29/01/2008 
29/01/2008 
SmPC, 
units within range of appr. pack size 
Labelling and 
Page 26/27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
Page 27/27 
 
 
 
 
 
 
 
